Irina Veytsman, MD
Hematology & Oncology · Harrisburg, PANPI 1457548307
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Teleflex LLC at 30.1% of the total. 2024 is the largest year on record at $71, 3.7 times the $19 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in PA, where the typical reported total is $1,277.
Across 4 payments — averaging $30.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$36
- Merck$35
- Pharmacyclics LLC, An Abbvie Company$30
- Novocure Inc.$19
Across 79 payments — averaging $5374.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$103K
- AstraZeneca$100K
- Amgen$82K
- Merck$63K
- Novocure Inc.$54K
- Janssen Research & Development, LLC$23K
What the payments were for
- Food & beverage$120100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 1 | $36 |
| Merck | 1 | $35 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $30 |
| Novocure Inc. | 1 | $19 |
How this compares
$120 in reported general payments places this provider in the 10th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 19 | $295,071 |
| EliquisApixaban | 36 | $25,443 |
| Levothyroxine Sodium | 34 | $960 |
| Pantoprazole Sodium | 29 | $161 |
| Ondansetron Hcl | 19 | $143 |
| Prochlorperazine Maleate | 11 | $126 |
| Dexamethasone | 13 | $114 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Harrisburg
- Kit LuHarrisburg$810K
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Usama GergisAllentown$1.2M
- Henry FungPhiladelphia$730K
- Alexander BarsoukPittsburgh$674K
- Abdalla SholiWilliamsport$576K
- Charu AggarwalPhiladelphia$541K
- Tracey EvansEast Norriton$500K
- Corey LangerPhiladelphia$492K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.